Original Publication Date: 1 January, 2015
Publication / Source: Clinical Investigation
Authors: Ali J Mahdi, Eamon J Mahdi & Steven Knapper
Better outcomes for patients with acute myeloid leukemia over the last 30 years have been largely achieved by improvements in supportive care measures rather than therapeutic advances. The combination of daunorubicin and cytarabine has remained the standard of care for patients undergoing intensive induction–consolidation treatment.